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Abstract Cofactor F420, a 5-deazaflavin involved in obliga-
tory hydride transfer, is widely distributed among archaeal
methanogens and actinomycetes. Owing to the low redox po-
tential of the cofactor, F420-dependent enzymes play a pivotal
role in central catabolic pathways and xenobiotic degradation
processes in these organisms. A physiologically essential
deazaflavoenzyme is the F420-dependent glucose-6-
phosphate dehydrogenase (FGD), which catalyzes the reac-
t ion F420 + glucose-6-phosphate → F420H2 + 6-
phospho-gluconolactone. Thereby, FGDs generate the reduced
F420 cofactor required for numerous F420H2-dependent reduc-
tases, involved e.g., in the bioreductive activation of the anti-
tubercular prodrugs pretomanid and delamanid. We report
here the identification, production, and characterization of
three FGDs from Rhodococcus jostii RHA1 (Rh-FGDs),
being the first experimental evidence of F420-dependent
enzymes in this bacterium. The crystal structure of Rh-
FGD1 has also been determined at 1.5 Å resolution, showing
a high similarity with FGD from Mycobacterium tuberculosis
(Mtb) (Mtb-FGD1). The cofactor-binding pocket and active-
site catalytic residues are largely conserved in Rh-FGD1 com-
pared with Mtb-FGD1, except for an extremely flexible inser-
tion region capping the active site at the C-terminal end of the
TIM-barrel, which also markedly differs from other structur-
ally related proteins. The role of the three positively charged
residues (Lys197, Lys258, and Arg282) constituting the bind-
ing site of the substrate phosphate moiety was experimentally
corroborated bymeans ofmutagenesis study. The biochemical
and structural data presented here provide the first step to-
wards tailoring Rh-FGD1 into a more economical biocatalyst,
e.g., an F420-dependent glucose dehydrogenase that requires a
cheaper cosubstrate and can better match the demands for the
growing applications of F420H2-dependent reductases in in-
dustry and bioremediation.
Keywords Rhodococcus . F420 . Deazaflavoenzymes .
Glucose-6-phosphate dehydrogenase
Introduction
The unusual cofactor F420, a 7,8-didemethyl-8-hydroxy-5-
deazariboflavin, was originally discovered in various archaea
(Cheeseman et al. 1972) (Fig. 1). It was demonstrated that in
both methanogenic and nonmethanogenic archaea, F420 rep-
resents a central catabolic redox cofactor involved in the oxi-
dation of energy sources (e.g., H2 and formate) (Jacobson
et al. 1982; Vitt et al. 2014; Tzeng et al. 1975a; Wood et al.
2003) and the reduction of cofactors such as NADP+ and
tetrahydromethanopterin (Tzeng et al. 1975b; Warkentin
et al. 2001; Hartzell et al. 1985; Aufhammer et al. 2005). In
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recent years, it has become clear by genome sequence analy-
ses and biochemical studies that the deazaflavin cofactor is
also utilized by numerous enzymes in actinobacteria, includ-
ing Mycobacterium tuberculosis (Mtb)—the notorious causa-
tive agent of tuberculosis (Daniels et al. 1985). In actinomy-
cetes, F420 was found to be involved in several important
processes such as biosynthesis of antibiotics in Streptomyces
spp. (e.g., tetracycline, lincosamide, and aminoglycoside)
(Wang et al. 2013; Coats et al. 1989; Li et al. 2009a), degra-
dation of coumarin derivatives (e.g., carcinogenic aflatoxins)
(Taylor et al. 2010; Lapalikar et al. 2012b; Ahmed et al. 2015),
and other aromatic compounds (e.g., picrate and related com-
pounds) (Ebert et al. 1999; Heiss et al. 2002; Jirapanjawat
et al. 2016). For mycobacteria, there is a compelling evidence
that F420 is essential to render the bacilli persistent in hostile
and challenging environments, such as anaerobic conditions,
and oxidative and nitrosative stress (Hasan et al. 2010;
Gurumurthy et al. 2013; Purwantini and Mukhopadhyay
2009). Interestingly, in vivo activation of the novel antituber-
cular nitroimidazole prodrugs—such as pretomanid (PA-824),
delamanid (OPC-67683), and TBA-354—strictly requires a
selective reduction of these prodrugs facilitated by an
F420H2-dependent reductase (Stover et al. 2000; Matsumoto
et al. 2006; Denny 2015). Owing to the newly discovered
mode of action, these nitroimidazole compounds are highly
promising as they exhibit no cross-resistance with the current
front-line antitubercular drugs in vitro and even exert activity
on non-replicating tubercle bacilli (Stover et al. 2000;
Matsumoto et al. 2006; Singh et al. 2008). Delamanid
(OPC-67683) was recently clinically approved for
multidrug-resistant tuberculosis whereas pretomanid (PA-
824) and TBA-354 are currently in phase III and phase I
clinical trials, respectively (Tasneen et al. 2015).
The discovery of this novel antimycobacterial class of
drugs is attracting an increasing interest in F420-dependent
enzyme research (Taylor et al. 2013). Due to the unique redox
potential (−340 mV) of F420, which is lower than that of FAD
(−220 mV) and even of the classical hydrogen carrier
NAD(P)+ (Jacobson and Walsh 1984; de Poorter et al.
2005), F420H2-dependent enzymes are capable of catalyzing
hydrogenation of a wide range of organic compounds which
are otherwise recalcitrant to reductive activation such as
enones (Taylor et al. 2010; Lapalikar et al. 2012b; Lapalikar
et al. 2012a) and imines (Coats et al. 1989; Li et al. 2009a; Li
et al. 2009b) in various heterocycles (Schrittwieser et al.
2015). These enzymes thus hold the promise of being highly
valuable in industrial biotechnology and bioremediation, and
can be exploited as a complement to the available toolboxes
for asymmetric chemical synthesis (Taylor et al. 2013;
Greening et al. 2016; Ney et al. 2016).
As most bacterial F420-dependent enzymes are involved in
catalyzing reductions, several F420-dependent dehydroge-
nases have evolved with the purpose to maintain a cytosolic
reservoir of reduced F420 (F420H2). In mycobacteria and other
actinomycetes, glucose-6-phosphate dehydrogenases (FGDs)
seem to be the main producer of F420H2, by catalyzing the
reaction F420 + glucose-6-phosphate → F420H2 + 6-
phosphogluconolactone (Fig. 1). FGD was first identified in
Mycobacterium smegmatis and subsequently in other actino-
mycetes, including Mtb (Purwantini and Daniels 1996;
Purwantini et al. 1997; Purwantini and Daniels 1998). Since
the identification of the first FGD two decades ago in Daniels’
lab (Purwantini and Daniels 1996), only two FGDs from ac-
tinomycetes, namelyM. smegmatis and Mtb, have been char-
acterized in detail (Bashiri et al. 2007; Bashiri et al. 2010).
These two FGDs share 37% sequence similarity and belong to
an F420-dependent enzyme subgroup within the luciferase-like
hydride transferase family. The affinity of both enzymes for
F420 and glucose-6-phosphate (G6P) falls in a comparable
range, facilitating the release of the resulting reduced cofactor
to be consequently exploited by downstream F420H2-depen-
dent enzymes. Heterologous expression in Escherichia coli of
both FGDs was found to be troublesome, often resulting in
formation of inclusion bodies. Structural characterization of
an FGD from Mtb has been recently described (Bashiri et al.
2008).
Rhodococci are high G+C content, Gram-positive aerobic,
non-sporulating actinomycetes of high biotechnological and
environmental importance due to their ability to catalyze an
array of unique enzymatic reactions (van der Geize and
Dijkhuizen 2004). A recent bioinformatic study suggested that
Rhodococcus jostii RHA1 is among the actinomycetes that
carry the largest number of F420-dependent enzymes. It was
predicted to possess at least 104 deazaflavoenzymes (Selengut
and Haft 2010). Nevertheless, up to date, there is no experi-
mental evidence for the presence of deazaflavoenzymes in
Fig. 1 Reaction catalyzed by F420-dependent dehydrogenase (FGD).
Glucose-6-phosphate is oxidized into 6-phosphogluconolactone by
FGD concomitantly with the formation of the reduced F420 coenzyme,
which is subsequently employed by various F420H2-dependent reductases
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R. jostiiRHA1. Therefore, in this work, we aimed to (1) verify
the existence of FGDs in R. jostii RHA1 (Rh-FGD) by heter-
ologous expression of putative FGD-encoding genes in
E. coli, (2) characterize the catalytic properties of the identi-
fied enzyme(s), and (3) obtain and analyze the crystal struc-
ture of a Rh-FGD.
Materials and methods
Expression and purification of Rh-FGD1 in E. coli
R. jostiiRHA1was grown in lysogeny broth (LB) at 30 °C; after
which, genomic DNA was extracted using the GenElute
Bacterial Genomic DNA kit from Sigma. Three putative fgd
genes , RHA1_RS43115 , RHA1_RS10755 , and
RHA1_RS43570, were amplified from R. jostii RHA1 genomic
DNA using Phusion High-Fidelity DNA polymerase (Thermo
Scientific) and the corresponding pairs of primers as listed in
Table 1. The purified PCR products (100–200 ng) were treated
with 0.5 U Taq polymerase (Roche) and 0.75 mM dATP by
incubation at 72 °C for 15 min to introduce the 3′-A overhangs.
The resulting insert DNA fragments were ligated into the pET-
SUMO vector according to the instruction manual of the
Champion pETSUMOexpression system (Invitrogen). The con-
struction of the Rh-FGD1 mutants K197N, K258N, and R282Q
was done by using the QuikChange® mutagenesis method with
primers (Table 1) designed by the web-based QuikChange®
Primer Design Tool (Agilent Technologies) and the pET-
SUMO-RHA1_RS43115 plasmid as template. All constructs
were confirmed by sequencing.
Proteins were initially expressed in E. coli BL21(DE3),
grown in Terrific broth containing 50 μg/mL kanamycin, 1%
(w/v) glucose, and induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 24 °C when the cells reached
OD600 ~0.7–0.8. To overcome the insolubility of the
overexpressed proteins in E. coli BL21(DE3), the expression
hosts were changed to E. coli C41(DE3) (Lucigen) for both the
wild-type and mutant Rh-FGDs. The culture conditions were
kept the same as for E. coliBL21(DE3), except for the addition
of 0.2% (w/v) glucose. The cells were grown until late station-
ary phase and harvested by centrifugation at 4600×g for 10 min
(Beckman–Coulter JA-10 rotor, 4 °C). Cells were resuspended
in lysis buffer (50mMKPi pH 7.8, 400mMNaCl, 100mMKCl,
10% (v/v) glycerol, 1 mM β-mercaptoethanol, 20 mM imidaz-
ole) and disrupted by sonication using a VCX130 Vibra-Cell
(Sonics &Materials, Inc., Newtown, USA) at 4 °C (5 s on, 10 s
off, 70% amplitude, total of 5 min). Following centrifugation at
20000×g for 45 min (Beckman–Coulter JA-25.5 rotor, 4 °C) to
remove unbroken bacteria and cellular debris, the supernatant
was applied onto a 5-mL HisTrap HP column (GE Healthcare)
pre-equilibrated in the same buffer. The recombinant enzyme
with the His-SUMO tag was eluted with a gradient from 20 to
500 mM imidazole in the same buffer. Fractions containing the
pure enzyme as indicated by SDS-PAGE and FGD activity
assay were pooled, desalted to remove imidazole, and concen-
trated in a 30-kDaMWCOAmicon (Milipore) centrifugal filter
unit. Protein concentration was estimated using the Waddell’s
method (Waddell 1956).
To obtain the native enzyme, the His-SUMO tag was cleaved
by incubating with 1% (mol/mol) SUMO protease (Invitrogen)
for 2 h at 4 °C. The His-SUMO tag, uncleaved protein, and
SUMOproteasewere removed by applying the cleavagemixture
onto a second HisTrap column. The native enzyme was concen-
trated and finally purified through a Superdex 200 10/300 GL
(GE Healthcare) in 10 mM HEPES pH 7.5, 100 mM NaCl, 10%
(v/v) glycerol, 1 mM β-mercaptoethanol prior to crystallization
experiments.
Thermostability
Analysis of Rh-FGD1 thermostability was based on the
unfolding temperature, Tm, determined by the use of the
Thermofluor® technique (Pantoliano et al. 2001) with a Bio-
Rad C1000 Touch Thermal Cycler (Bio-rad Laboratories, Inc.)
in 96-well plates. Each well had a final volume of 25 μL con-
taining 1.6 μM Rh-FGD, 5 × SYPRO Orange (Invitrogen),
buffers, and/or additives. The protein start buffer was exchanged
to 50mMKPi pH 7.8 and 150mMNaCl for the buffer screen and
to 50 mM KPi pH 7.8, 500 mM NaCl, and 100 mM KCl for the
Table 1 List of primers used in this study
fgd genes Forward primers (5′–3′) Reverse primer (5′–3′)
RHA1_RS43115 (Rh-FGD1) ATGGTGATCAAGTTCGGGTAC TCATGCGAGCCCTCGCAG
RHA1_RS10755 (Rh-FGD2) CTACCCCCGCAGCCG ATGGCCCACGAACTCAAGC




The mutation sites were indicated as underlined oligonucleotides
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additive screen. The compositions of the buffers and additives are
described in Boivin et al. (Boivin et al. 2013).
Spectrophotometric assay for FGD activity
FGDactivitywas routinelymonitored by following the reduction
of F420 at 420 nm, 25 °C, and pH 7.5 using an absorption coef-
ficient ε420 nm of 41.4 mM
−1 cm−1 (Eirich et al. 1978; Purwantini
et al. 1992) in a V-650 spectrophotometer from Jasco (IJsselstein,
The Netherlands). F420 was isolated from M. smegmatis as pre-
viously described (Bashiri et al. 2010; Isabelle et al. 2002)
(M. smegmatis mc2 4517 and the plasmid pYUBDuet-FbiABC
were kind gifts from Dr. G. Bashiri, the University of Auckland,
New Zealand). The assay mixture typically contained 50 mM
Tris/HCl pH 7.5, 300 mM NaCl, 1 mM β-mercaptoethanol,
1 mM EDTA, 100 nM enzyme, 20 μM F420, and 1 mM glucose-
6-phosphate (G6P) in a final volume of 500 μL. For steady-state
kinetics, 10 nM enzyme was used in the same buffer except for
the experiments with glucose that were performed with 500 nM
enzyme. Kinetic data were analyzed using nonlinear regression
to the Michealis–Menten equation using GraphPad Prism v. 6.0
(GraphPad Software Inc., La Jolla, CA, USA). For the pH opti-
ma determination, the reactions contained 40 mM Britton-
Robinson buffer (Britton and Robinson 1931), 100 nM enzyme,
and 20 μM F420 and were initiated by adding 1 mM G6P. In the
experiments, enzyme activity was monitored at 401 nm (an
isosbestic point of F420; ε401 nm = 25 mM
−1 cm−1) (Jacobson
et al. 1982; DiMarco et al. 1990) for 5 min.
Substrate profiling
Alternative phosphate-sugar substrates for FGDwere screened in
a SynergyMXmicroplate spectrophotometer (BioTek) using 96-
well plates with clear bottom. The reaction mix (200 μL)
contained 100 nM enzyme, 10 mM substrate, and 29.6 μM F420
in the same buffer as described in the general spectrophotometric
assay. The tested compounds for substrate profiling were D-glu-
cose, D-mannose-6-phosphate, D-fructose-6-phosphate, α-D-glu-
cose-1-phosphate, α-D-galactose-1-phosphate, and D-glucos-
amine-6-phosphate. The absorbance of F420 at 420 nmwasmon-
itored in intervals of 45 s for 1 h.
Crystallization, X-ray data collection, and structural
determination of Rh-FGD1
Native Rh-FGD1 crystals were obtained using the sitting-drop
vapor diffusion technique at 20 °C by mixing equal volumes of
9.0mg/mL protein in 10mMHEPES pH 7.5, 10% (v/v) glycerol,
100mMNaCl, 1mMβ-mercaptoethanol and of themother liquor
containing 0.16 M ammonium sulfate, 0.08 M sodium acetate
pH 4.6, 20% (w/v) PEG 4000, and 20% (v/v) glycerol. X-ray
diffraction data were collected at the PXI and PXIII beamlines
of the Swiss Light Synchrotron in Villigen, Switzerland (SLS),
and at the ID23-1 beamline of the European Synchrotron
Radiation Facility in Grenoble, France (ESRF). Image integra-
tion and data scaling were processed with MOSFLM (Battye
et al. 2011) and programs of the CCP4 suite (Winn et al.
2011). Detailed data processing statistics are shown in Table 2.
The Rh-FGD1 structure was initially solved by molecular re-
placement using MOLREP (Vagin and Teplyakov 2010) using
the coordinates of FGD1 from M. tuberculosis (PDB ID code
3B4Y) (Bashiri et al. 2008) as the search model devoid of all
ligands and water molecules. Model building and structure anal-
ysis was carried out with COOT (Emsley and Cowtan 2004)
whereas alternating cycles of refinement was performed with
REFMAC5 (Murshudov et al. 1997). Figures were created by
CCP4mg (McNicholas et al. 2011); atomic coordinates and
structure factors were deposited in the Protein Data Bank under
the PDB ID code 5LXE.
Results
Expression and purification of Rh-FGDs in E. coli
Three genes encoding putative homologs of Mtb-FGD (ac-
cession number KBJ40183) (Bashiri et al. 2007; Bashiri
et al. 2008) were identified by BLAST: RHA1_RS43115
Table 2 Data collection and refinement statistics
PDB ID Code 5LXE
Space group P212121
Resolution (Å) 1.47
a, b, c (Å) 81.4, 88.1, 88.8
Rsym
a,b (%) 5.0 (55.0)






Sulfate/glycerol/water 2 × 5/2 × 6/571
Average B value for all atoms (Å2) 25.0
Rcryst
b,c (%) 16.2 (27.1)
Rfree
b, c (%) 18.5 (25.1)
Rms bond length (Å) 0.021
Rms bond angles (°) 2.02
Ramachandran outliers 0
aRsym =∑|Ii − <I > |/∑Ii, where Ii is the intensity of ith observation and I is
the mean intensity of the reflection
bValues in parentheses are for reflections in the highest resolution shell
cRcryst = ∑|Fobs − Fcalc|/∑|Fobs| where Fobs and Fcalc are the observed and
calculated structure factor amplitudes, respectively. Rcryst and Rfree were
calculated using the working and test sets, respectively
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(WP_011600337.1), RHA1_RS10755 (WP_011595003.1),
and RHA1_RS43570 (WP_011600440.1) (with 84, 84, and
83% sequence identity to Mtb-FGD1, respectively). These
genes were amplified from R. jostii RHA1 genomic DNA,
cloned into the pET-SUMO vector, and expressed in E. coli
C41(DE3) as N-terminal SUMO-hexahistidine-fused pro-
teins using IPTG as an inducer. The cultivation conditions
were optimized for the production of the soluble and active
proteins, resulting in a 48-h growth at 24 °C with 1 mM
IPTG in Terrific broth as the most effective condition. By
testing the cell extracts containing all three different proteins
(RHA1_RS43115, RHA1_RS10755, and RHA1_RS43570
referred to as Rh-FGD1, Rh-FGD2, and Rh-FGD3, respec-
tively), it was found that they all exhibit FGD activity. Rh-
FGD1 and Rh-FGD2 exhibited comparable specific activity
whereas Rh-FGD3 was >20-fold less active. We focused our
exploration on the best expressed FGD, namely Rh-FGD1.
Typically, approximately 80 mg of pure Rh-FGD1 was ob-
tained from 1 L of TB culture. Furthermore, it is worth
noting that Rh-FGD1 is flanked by genes putatively
encoding a 6-phosphogluconate dehydrogenase and a G6P




Rh-FGD1 displayed an optimum for activity on glucose-
6-phosphate at pH 7.5–8.0 (Fig. 2); this is somewhat
similar to the FGDs from Mtb [6.5–7.0 (Bashiri et al.
2008)] and from M. smegmatis [two separate pH optima:
6.0 and 8.0 (Purwantini and Daniels 1996)]. For further
studies on Rh-FGD1, pH 7.5 was chosen to monitor
FGD activity.
Substrate profiling
Rh-FGD1 is strictly dependent on F420 as coenzyme. The
enzyme did not show any significant activity when NAD+,
NADP+, FAD, or FMN was used as alternative electron ac-
ceptors. Rh-FGD1 was also found to be highly specific for
G6P as electron donor. All tested alternative phosphate-sugars
displayed significantly lower activity when compared to G6P.
10 mM D-mannose-6-phosphate, D-fructose-6-phosphate, and
D-glucosamine-6-phosphate reached only 1.1, 4.8, and 2.8%
of the rate obtained with 1 mM G6P, respectively. The free
anomeric carbon C1 of the sugar is crucial for the dehydroge-
nation as no detectable FGD activity was observed with α-D-
glucose-1-phosphate and α-D-galactose-1-phosphate. Rh-
FGD1 accepted D-glucose as substrate, although with very
low catalytic activity.
Thermostability
The thermostability of Rh-FGD1 was evaluated by determin-
ing apparent melting temperatures (Tm) using the Thermofluor®
technique (Pantoliano et al. 2001). This revealed that Rh-FGD1
represents a stable enzyme, exhibiting Tm values above 35 °C in
most common buffer systems (Fig. 3). The best stabilizing
buffers were HEPES, citrate, and phosphate. Several additives
were found to have significant effects on the thermostability of
Rh-FGD1. NaCl, glycerol, and divalent cations (e.g., Mg2+,
Ca2+, and Mn2+) exerted marked effects, resulting in Tm values
of above 55 °C. The stabilizing effect of NaCl depends
greatly on its concentration: an increase in NaCl concentration
from 50 mM to 1 M (in either HEPES or Tris/HCl) drastically
elevates the Tm by around 20 °C. Based on these findings, we
typically stored Rh-FGD1 in a phosphate-based buffer with
both NaCl and glycerol as additives. Remarkably, the enzyme
can retain >90% of its activity after 1 year when being stored
at −80 °C.
Steady-state kinetics
For determining the steady-state kinetic parameters with F420 and
glucose-6-phopshate as substrate, Rh-FGD1 activity was moni-
tored following the decrease in absorbance at 420 nm associated
with the reduction of F420. The kinetic data did fit well when
using the Michaelis–Menten kinetic model. The kinetic parame-
ters for the natural substrates G6P and F420 were determined
(Table 3) by keeping one of the substrates constant (F420 at
20 μM or G6P at 2.0 mM, respectively), while varying the other
substrate concentration. The apparent Km values for G6P and
F420 are 0.31 mM and 3.8 μM, respectively. The Km value for
F420 is very similar to that observed with FGDs from Mtb
(Kd = 4.5 μM) and M. smegmatis (4 μM) (Purwantini and
Daniels 1996; Bashiri et al. 2008). The Km value for G6P is
closer to that for Mtb-FGD (0.1 mM) whereas it is much lower






















Fig. 2 Effect of pH on Rh-FGD1 activity. The reaction contains 40 mM
Britton–Robinson buffer, 100 nM Rh-FGD1, 20 μM F420, and 1.0 mM
G6P, and activity was monitored by following the absorbance at
401 nm (isosbestic point of F420) for 300 s at 25 °C
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than the equivalent value from FGD inM. smegmatis (1.6 mM).
The observed differences in Km values for G6P can partly be
explained by different levels of G6P in these organisms; e.g., it
is known that mycobacterial cells can contain high levels of G6P
(Hasan et al. 2010; Purwantini and Daniels 1996).
As the FGD-catalyzed reaction involves two substrates,
G6P and F420, we set out to decipher which mechanism is
operative for Rh-FGD1, namely a ping-pong, sequential, or
random mechanism. Both substrate concentrations were var-
ied, and the F420 reduction rates were measured accordingly.
Increasing concentrations of both substrates G6P and F420
resulted in an increase in reaction rates, suggesting that the
reaction occurs via a ternary complex Rh-FGD1:G6P:F420.
This is best illustrated by the observed intersection of the lines
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Fig. 3 Melting temperatures of Rh-FGD1 in different buffer (a) and
additive (b) conditions measured by the Thermofluor® technique. Buffers
were used at a concentration of 100 mM unless otherwise indicated. The
error bars represent SD from the three replicates. Buffer A succinic acid/
NaH2PO4/ glycine = (2:7:7). Buffer B citric acid/ CHES/ HEPES = (2:4:3).
Ac acetate, Am ammonium, DTT dithiothreitol
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when double reciprocal values of the reaction rates and sub-
strate concentrations are plotted (Fig. 4). Whether these two
substrates bind in an ordered or a random manner, however,
remains to be further investigated, e.g., by product inhibition
or tracer studies with radioactive labeled substrates.
FGD1 overall structure
The crystal structure of Rh-FGD1 was determined at 1.47 Å
resolution by molecular replacement using Mtb-FGD1 devoid
of all ligands (PDB ID code 3B4Y) (Bashiri et al. 2008) as the
search model. The asymmetric unit contains two enzyme
monomers forming a compact dimer (Fig. 5a), which is also
observed in solution as estimated by gel permeation analysis
(data not shown), similarly to the mycobacterial homolog
(1.0 Å rmsd difference for 610 pairs of Cα atoms) (Fig. 5b).
The very good quality of the electron density enabled us to
model several residues in a double conformation and to iden-
tify a residue with a cis peptide bond in proximity of the active
site (Fig. 5c). Only residues 254–263 in subunit A, and 250–
279 in subunit B lack clear electron density and were therefore
excluded from the final model. Each Rh-FGD1 monomer is
comprised of residues 1–334, forming an (α/β)8 TIM-barrel,
with the active site typically located at the C-terminus of the
barrel, as observed in Mtb-FGD1 (Bashiri et al. 2008). As
indicated by the Dali server (Holm and Rosenstrom 2010),
this protein topology is shared also with other homologous
members of the luciferase-like hydride transferase family, in-
cluding a secondary alcohol dehydrogenase (Adf) and a
methylene-tetrahydromethanopterin reductase (Mer) (34 and
25 sequence identity with Rh-FGD1, respectively)
(Aufhammer et al. 2004; Aufhammer et al. 2005). The two
Rh-FGD1 molecules present in the asymmetric unit are essen-
tially identical, as indicated by an overall rmsd difference of
0.55 Å in Cα atomic positions of 302 residues, except for a
segment comprising residues 41–49, which was excluded in
the noncrystallographic symmetry restrained refinement. The
dimer interface area is rather large, burying approximately
2000 Å2 [as analyzed by the program PISA (Krissinel and
Henrick 2007)] and accounting for ~14% of the monomer’s
surface. Unless explicitly stated, hereafter, we will refer to
monomer A for describing the structure.
F420 binding site
All attempts to elucidate the structure of Rh-FGD1 in its ho-
loenzyme form, i.e., with the F420 cofactor bound, were un-
successful. Nonetheless, the obtained overall structure is sub-
stantially identical to that of the F420-bound Mtb-FGD1 and
the architecture of the active site is conserved. Therefore, the
Table 3 Steady-state kinetic
parameters for the wild-type Rh-
FGD1, K197N Rh-FGD1,
K258N Rh-FGD1, and R282Q
Rh-FGD1 for G6P and glucose
Rh-FGD1 Glucose-6-phosphate Glucose
Km [mM] kcat [s
−1] kcat/Km
[M−1 s−1]
Km [mM] kcat [s
−1] kcat/Km
[M−1 s−1]
wild type 0.31 ± 0.016 17 ± 0.32 57,000 >300 >0.015 0.056
K197N 95 ± 12 3.8 ± 0.29 40 >300 >0.020 0.072
K258N 61 ± 5.1 0.57 ± 0.024 9.4 >300 >0.0009 0.0039
R282Q >100 >0.047 0.67 >300 >0.0045 0.0018
a b 

















































Fig. 4 Two-substrate kinetic analysis for Rh-FGD1 via double reciprocal plots of reaction rates against a G6P or b F420 concentrations. These lines
intercept at one point, corresponding to the formation of a ternary complex Rh-FGD1:G6P:F420 to generate 6-phosphogluconolactone and F420H2
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F420 molecule was tentatively modeled in the Rh-FGD1 as a
result of the superposition of the mycobacterial enzyme struc-
ture (Fig. 5b, c). In particular, the high - quality electron den-
sity clearly indicates the presence of a well-ordered nonprolyl
cis-peptide bond between Ser72–Val73 constituent of a bulge
at the end of a β strand close to the presumed binding site of
the F420 isoalloxazine ring (Fig. 5c). This unusual cis-peptide
is highly conserved in this enzyme family, being consistently
observed in Mtb-FGD1, Adf, and Mer (joining Ser74–Val75,
Cys72–Ile73 and Gly61–Val62, respectively). This bulge is
essential as it serves as a backstop to hold the isoalloxazine
ring from its re-face, bending the deazaisoalloxazine ring into
a butterfly conformation (Aufhammer et al. 2005; Bashiri
et al. 2008; Aufhammer et al. 2004). The F420 binding pocket
is largely identical among FGDs, Adf, and Mer wherein the
deazaisoalloxazine ring locates at the innermost part of the
pocket and the hydrophilic polyglutamate tail extends into
the solvent (Figs. 5d and 6). The most noticeable difference
between the various structures of F420-binding proteins is a
helical coil region located at the C-terminus of the TIM-barrel,
creating a sort of lid element that stabilizes cofactor binding
(Fig. 6). In Rh-FGD1, the sequence for this structural element
is shorter than that of the homologous enzymes and corre-
sponds to the disordered part (residues 254–263 in monomer
A). The high flexibility of this region may correlate with a
more dynamic interaction with the cofactor and may well
explain the difficulty in obtaining the Rh-FGD1 structure in
its holoenzyme form.
Glucose-6-phosphate binding site
InMtb-FGD1, a citrate molecule, most likely derived from the
crystallization solution, was found to bind adjacent to the F420
molecule and later proved to be a competitive inhibitor for
Mtb-FGD1. Citrate occupies a cavity with a size that can fit
G6P in an orientation that is suitable for catalysis. This
allowed the modeling of G6P into the active site of Mtb-
FGD1, revealing highly conserved residues involved in sub-
strate binding and catalysis (Bashiri et al. 2008) (Fig. 5d). It
has been postulated that in Mtb-FGD1, the phosphate moiety
a b
c d
Fig. 5 Crystal structure of Rh-FGD1 from Rhodococcus jostii RHA1. a
Ribbon diagram of the Rh-FGD1 dimer showing the (α/β)8 TIM-barrel
architecture of the two monomers colored in light blue (monomer A) and
green (monomer B), respectively. The disordered region in each
monomer is represented by a dashed line corresponding to residues
254–263 and 250–279 in monomers A and B, respectively. b
Superposition of the Rh-FGD1 dimer (colored as in a) onto the
homologous Mtb-FGD1 [in white, 84% sequence identity, PDB ID
3Y4B (Bashiri et al. 2008)] with its F420 cofactor bound (carbon,
oxygen, nitrogen, and phosphorus atoms in white, red, blue and
magenta, respectively). c The nonprolyl cis peptide bond (connecting
Ser72 and Val73) and Met74 in a double conformation (sulfur atoms in
green) are fitted to the initial 2Fo − Fc electron density map contoured at
1.2 σ (brown chicken-wire). As a reference, the cofactor F420 from the
Mtb-FGD1 structure (superposed as in b) is drawn with shaded colors. d
Close-up of the Rh-FGD1 active site superposed to Mtb-FGD1 as in b.
The Mtb-FGD1 inhibitor citrate (carbon in gray) is shown bound to the
active site. Putative residues involved in substrate binding are labeled
with the corresponding Mtb-FGD1 residues in parentheses. The δ, ϵ
carbon and ζ nitrogen atoms of K197, and the guanidinium group of
R282 side chains were not visible in the electron density and were not
included in the final model
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of G6P occupies a positively charged pocket constituted by
side chains of Lys198, Lys259, and Arg283 (corresponding to
Ly s 1 9 7 , Ly s 2 5 8 , a n d A r g 2 8 2 i n R h - FGD1 ,
respectively) (Bashiri et al. 2008) (Fig. 5b). In Rh-FGD1, out
of the three residues, the position of Lys258 is unknown as it is
part of the disordered region. Instead, Lys197 and Arg282 are
visible and adopt a similar conformation with respect to the
corresponding residue in Mtb-FGD1. Nevertheless, a part of
their side chains lacks clear electron density (Cδ, Cϵ, and Nζ
of the former and the guanidinium group of the latter), which
indicates a much higher flexibility. Sequence alignment indicat-
ed that the three residues are strictly conserved in proteins
exhibiting FGD activity (Bashiri et al. 2008). Rv0132c—shar-
ing 36% sequence identity with Mtb-FGD1 and previously
annotated as Mtb-FGD2—does not contain these phosphate
group binding residues and consistently showed no such
assigned activity (Bashiri et al. 2012). In fact, Rv0132c was
later proven to be an F420-dependent hydroxymycolic acid de-
hydrogenase and was proposed to be an unprecedented antitu-
bercular target that may also be inhibited by the novel drug
pretomanid (PA-824) (Purwantini and Mukhopadhyay 2013).
To further probe the roles of these residues, we generated
single mutations, namely K197N, K258N, and R282Q Rh-
FGD1. In comparison to the wild-type Rh-FGD1, the mutants
showed a drastic decrease in catalytic efficiency for G6P, as
indicated byKm values of two orders of magnitude higher than
that of the wild-type enzyme (Table 3). The rate of catalysis
was also considerably affected: The R282Q mutant virtually
lost activity whereas the K197N and K258N mutants had a
4.5- and 30-fold lower kcat value, respectively, compared with
the wild type. Disruption of the phosphate binding pocket
may, to a certain extent, also affect the substrate specificity.
In fact, when glucose was used as a substrate instead of G6P,
the mutant K197N showed a slightly improved kcat/Km when
compared with the wild-type enzyme (Table 3). These data
unequivocally verified that the three targeted residues are cru-
cial for the binding of the phosphate moiety of the G6P.
Moreover, it might become possible to improve FGD activity
towards glucose, e.g., by random mutagenesis of residues
forming the G6P binding pocket.
Discussion
Physiological role of Rh-FGDs
F420 is an unusual redox cofactor originally found exclusively in
a restricted number of microbes, such as archaea and actinomy-
cetes. Astonishingly, a bioinformatics study in 2010 indicated
that F420 can be much more widespread than previously thought
and present in 11% of all sequenced bacteria and archaea
(Selengut and Haft 2010). In particular, R. jostii RHA1 was
predicted to contain at least 104 deazaflavoenzymes, an impres-
sively large number. In line with this prediction, we present here
the first experimental evidence for the presence of F420-depen-
dent enzymes in R. jostii RHA1. More specifically, the R. jostii
RHA1 genome encodes at least three FGDs: RHA1_RS43115
(WP_011600337.1), RHA1_RS10755 (WP_011595003.1), and
RHA1_RS43570 (WP_011600440.1) (referred to as Rh-FGD1,
Rh-FGD2, and Rh-FGD3, respectively). We have focused our
exploration on Rh-FGD1, the best expressed one, characterized
the kinetic properties and elucidated the structure of the apo
protein at high resolution. On a cautionary note, it should be
noticed that the Rh-FGD1 and Rh-FGD3 are plasmid encoded
whereas Rh-FGD2 is instead encoded by a chromosomal gene.
Preliminary tests (data not shown), however, indicated that Rh-
FGD1 and Rh-FGD2 have comparable specific activity. This
gene redundancy is generally believed to facilitate the high cat-
abolic versatility in rhodococci (van der Geize and Dijkhuizen
2004; McLeod et al. 2006).
F420-dependent glucose-6-phosphate dehydrogenase has
been suggested to be the primary enzyme responsible for the
F420 reduction in several actinomycetal genera, including
mycobacteria, thereby linking their central metabolism to the
F420 reduction reaction (Purwantini and Daniels 1996). The
main role of mycobacterial FGDs appears to be the generation
of F420H2 as these bacilli also encode the conventional
NADP+-dependent FGDs (Purwantini et al. 1997), which
Fig. 6 Comparison between the active site of Rh-FGD1 (blue) with that of
Mtb-FGD1 (3B4Y,white), Adf (1RHC, coral), andMer (1Z69, green). For
clarity, only the F420 from Mtb-FGD1 is shown. The insertion regions of
Mtb-FGD1, Adf, and Mer corresponding to the highly disordered segment
in Rh-FGD1 (residues 254–263, represented by a dashed line) are
highlighted in bold style. The orientation of the molecule is
approximately 90° rotated along an axis perpendicular to the plane of the
paper with respect to that in Fig. 5c. Color coding for atoms is as in Fig. 5b
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interestingly showed no significant phylogenetical relation to
FGDs (Purwantini and Daniels 1998). A deletion of either fgd
or fbiC—a gene involved in the biosynthesis of F420—renders
these mycobacterial strains incapable of reducing xenobiotics
via F420H2-dependent reductases (Taylor et al. 2010; Hasan
et al. 2010; Stover et al. 2000; Manjunatha et al. 2006).
Nevertheless, the physiological role of FGDs in
Rhodococcus spp. remains largely unclear. It is well known
that in Rhodococcus opacus and Nocardioides simplex, the
reduced F420 is supplied mainly by F420:NAPDH oxidoreduc-
tases (FNOs) rather than FGDs (Ebert et al. 1999; Heiss et al.
2002; Ebert et al. 2001; Heiss et al. 2003). FNOs were found
to be expressed from the same operon as the F420H2-depen-
dent hydride transferases, which are responsible for the deg-
radation of environmental nitroaromatic compounds such as
picrate and 2,4-dinitrophenols (Ebert et al. 1999; Heiss et al.
2002; Ebert et al. 2001). However, it cannot be excluded that
FGDs also play a (crucial) role in generating F420H2. As very
little is known about the natural substrates of the F420H2-de-
pendent enzymes in Rhodococcus spp., it can be speculated
that FGDs are primarily responsible for providing the reduc-
tant for the endogenous metabolism, maintaining the redox
homeostasis during normal growth or in response to oxidative
stress as observed in mycobacteria. Several lines of evidence
have revealed the pivotal role of G6P as an electron reservoir
mobilized via FGDs in protecting mycobacteria against oxi-
dative and nitrosative stress (Hasan et al. 2010; Gurumurthy
et al. 2013). In fact, the presence of a NADP+-dependent FGD
alone failed to render aM. smegmatismutant deficient in FGD
capable of surviving oxidative stress. Further investigations,
e.g., gene deletion studies in combination with isotopic label-
ing metabolomics, are therefore necessary to decipher the pre-
cise role of FGDs in rhodococci (van der Geize et al. 2008).
FGDs as biocatalyst for cofactor regeneration
The biocatalytic reduction of F420 has been carried out so far
with the use of Mtb-FGD1 (Manjunatha et al. 2006). Such
reduced F420 is essential in studying deazaflavin-dependent re-
ductases. However, mycobacterial FGDs are poorly to moder-
ately expressed as soluble protein when E. coli is used as a
heterologous expression host (Purwantini and Daniels 1998;
Bashiri et al. 2007; Manjunatha et al. 2006). To overcome this
limitation, a dedicated M. smegmatis expression strategy was
developed to enhance the solubility of mycobacterial proteins.
The typical yield obtained was 7 mg of pure recombinant Mtb-
FGD1 from 1 L of M. smegmatis culture (Bashiri et al. 2007).
In contrast, we produced soluble Rh-FGD1 in rather high yield:
80 mg of pure protein L−1 of culture. The developed E. coli-
based expression system facilitates the routine production of
soluble FGD which can be used for the synthesis of reduced
F420. Rh-FGD1 is a relatively fast enzyme, with a kcat of 17 s
−1
for G6P (Table 3). In addition, Rh-FGD1 appears to be
thermostable in most common buffers and additives (Fig. 3);
upon storage at −80 °C, Rh-FGD1 retained >90% activity after
1 year. The observation that Rh-FGD1 displayed some activity,
yet very low (Table 3), with glucose, a much cheaper substrate
instead of G6P, hints to the possibility to engineer Rh-FGD1
into a more efficient F420-dependent glucose dehydrogenase.
The first logical target for such tailoring efforts would be the
phosphate binding pocket. Interestingly, when glucose was
used as substrate, the mutant K197 N showed an improved
kcat/Km value of 30% higher than that of the wild type.
Therefore, by fine-tuning these residues by site-directed muta-
genesis, one could obtain mutants with improved activity with
the cheap cosubstrate glucose. Given its robustness and acces-
sibility, Rh-FGD1 represents a potential candidate for the bio-
catalytic reduction of F420 in larger scale or in fusion with other
valuable F420H2-dependent reductases in a redox self-sufficient
whole-cell biotransformation.
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